An interventional study of Cognitive Behavioural Therapy and Physical Exercise in Generalized Anxiety Disorder, sponsored by Solli Distriktspsykiatriske Senter. Active, not recruiting at 1 site in Norway. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Solli Distriktspsykiatriske Senter · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Generalised anxiety disorder (GAD) is a severe and debilitating anxiety disorder that is highly prevalent among older adults. Anxiety and GAD is a well-documented risk factor for the development of other severe conditions such as depression and dementia, and effective treatments are called for. However, recommended treatment for GAD has consistently been found to yield blunted response rates for older adults compared to younger patients.
The purpose of this study is to evaluate the effects of exercise-augmented cognitive behaviour therapy for older adults with GAD. Exercise augmented CBT is expected to yield better results than standard CBT in terms of greater reduction of symptoms and increased rates of remission. The investigators will also investigate the effects of treatment on biological, physiological and neuropsychological measures.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
This study's enrollment of 53 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Browse Generalized Anxiety Disorder studies →Solli Distriktspsykiatriske Senter is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
Behavioral: Cognitive Behavioural Therapy · Behavioral: Physical Exercise
Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
Behavioral: Cognitive Behavioural Therapy · Behavioral: Placebo control
Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
Also known as: Telephone follow-up
Changes in The Penn State Worry Questionnaire
Assesses symptom severity of GAD
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Change in clinical diagnosis after treatment assessed by independent, blinded rater with Anxiety Disorders Interview Schedule (ADIS-IV)
Remission rates. Assessed by independent, blinded rater with Anxiety Disorders Interview Schedule (ADIS-IV)
Time frame: Baseline and post-treatment (up to 20 weeks after baseline)
Geriatric Anxiety Inventory
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Generalized Anxiety Disorder 7-item scale (GAD-7)
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Beck Anxiety Inventory
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Beck Depression Inventory - II
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Bergen Insomnia Scale
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Quality of Life Inventory
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
International Physical Activity Questionnaire (IPAQ)
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
5-item Treatment Credibility and Expectancy Scale (CES)
Time frame: Baseline
Function and structure of prefrontal lobes and limbic system
Functional Magnetic Resonance Imaging (fMRI) conducted with a 3-Tesla scanner.
Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up
Blood samples
Serum concentrations of mature and pro brain-derived neurotropic factor
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Saliva samples
To measure cortisol
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Three subtests from Delis-Kaplan Executive Function System battery (D-KEFS; Delis, Kaplan & Kramer, 2001)
Measures executive function
Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up
Wisconsin Card Sorting Test: Computer Version 4 research edition (WCST-CV4; Heaton, PAR staff & Goldin 2003).
Measures executive function
Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up
The California Verbal Learning Test (CVLT; Delis, Kramer & Kaplan, 1994).
Measures memory
Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up
Wechsler Abbreviated Scale of Intelligence
Two subtests from Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) will be administered to assess IQ level.
Time frame: Baseline
Ambulatory Electrocardiogram (ECG)
Measures heart rate variability (HRV)
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Ekblom-Bak submaximal ergometer cycle test
Test for prediction of VO2 max, which gives an indication of physical fitness
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Strength test battery
Measures submaximal physical strength, which gives an indication of physical fitness.
Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up
Plan to share: No
Ran from Mar 2016 to primary completion in Oct 2023, 91 months.
Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's 91 months is above that.
Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →
Solli Distriktspsykiatriske Senter